Skip to main content
Premium Trial:

Request an Annual Quote

Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

 

NEW YORK (GenomeWeb) – Oncgnostics announced recently that it has received an extended CE-IVD mark for the GynTect cervical cancer assay. As a result, researchers can run the assay on Roche Diagnostics' Cobas z 480 quantitative PCR-based analyzer.

According to Jena, Germany-based Oncgnostics, the assay allows researchers to detect modified and methylated DNA regions, which specifically occur in cervical cancer. It noted that the GynTect assay requires a two-step process, chemical treatment with bisulphite to fixate the DNA methylation of the diagnostic material, followed by PCR to detect marker regions. During the PCR step, only methylated DNA regions in the sample are amplified.

Oncgnostics CEO and cofounder Alfred Hansel said that before the extension of its CE-IVD mark, GynTect could be run only with Life Technologies' ABI 7500 Real-Time PCR system. "With [Cobas z 480's] widespread availability, many more laboratories now can perform GynTect without any additional expenses," he said in a statement.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.